Available Forms: Oral Solution
Available Strengths: 0.75 mg/mL
Reference Brands: Evrysdi (USA/EU)
Category: Neurology
Risdiplam is an oral survival motor neuron 2 (SMN2) splicing modifier used to treat spinal muscular atrophy (SMA) in adults and children aged 2 months and older. It works by increasing the production of functional SMN protein, essential for maintaining motor neuron function. Risdiplam helps improve muscle strength and slow disease progression in SMA patients.
Quick Response Guaranteed | Verified Suppliers
Risdiplam is used for the treatment of spinal muscular atrophy (SMA) in patients two months of age and older.
Risdiplam is made from a small-molecule splicing modifier that increases the production of functional survival motor neuron (SMN) protein in the body.
The trade name of Risdiplam is Evrysdi.
Risdiplam is made by Genentech, a member of the Roche Group, in collaboration with PTC Therapeutics and the SMA Foundation.
The generic name of the product is Risdiplam.
The brand name of Risdiplam is Evrysdi.
Risdiplam is manufactured by Genentech, Inc. in the United States.
Strength: 125 mg/mL, 200 mg, 250 mg, 300 mg, 500 mg, 100 mg/mL
Form: Tablet / Capsule/ Injection / Oral syrup
Reference Brands: Depakene (USA), Depakine (EU/LATAM), Valprol (India)
Strength: 50 mg, 100 mg
Form: Tablets
Reference Brands: Ubrelvy (USA/India)
Strength: 100 mg
Reference Brands: Tasmar (USA/EU)
Strength: 50 mg ,100 mg
Reference Brands: Xadago (USA/EU)
By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under ‘Fair use.’
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Stay updated on pharma trends and marketplace opportunities.
Online · B2B Pharma · Medical Tourism · NPP